Recursion Pharmaceuticals, INC Form 4 insider transactions

Blake Borgeson, a Director of Recursion Pharmaceuticals, Inc., sold 30,000 shares of common stock on August 4, 2026 for $3.25 per share.

Blake Borgeson, a director at Recursion Pharmaceuticals, Inc., has reported the sale of 40,000 shares of Class A Common Stock.

Dar Zavain, a Director at Recursion Pharmaceuticals, received a stock grant under the company's Outside Director Compensation Policy.

Dean Y. Li, a Director at Recursion Pharmaceuticals, received a stock grant of 3,747 shares of Class A Common Stock on July 1, 2026.

Recursion Pharmaceuticals CFO Ben R. Taylor disposed of 5,396 shares to satisfy tax obligations related to restricted stock units.

Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock via a pre-arranged 10b5-1 plan.

Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock under a pre-arranged trading plan.

Director Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals (RXRX) at $3.54 per share via a Rule 10b5-1 plan.

Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals common stock under a pre-arranged 10b5-1 trading plan.

Director Christopher Gibson of Recursion Pharmaceuticals reported a transaction involving Class A Common Stock, executed under a Rule 10b5-1 trading plan.

Chief Scientific Officer David Hallett disposed of 26,657 shares of Recursion Pharmaceuticals to satisfy tax obligations.

CEO Najat Khan disposed of 62,701 shares of Recursion Pharmaceuticals to satisfy tax obligations related to restricted stock units.

Recursion Pharmaceuticals CFO Ben Taylor disposed of 25,018 shares to satisfy tax obligations related to restricted stock units.

Director Christopher Gibson reported the net settlement of 22,821 shares of Class A Common Stock for tax obligations.

Director Christopher Gibson executed a conversion and sale of Class A Common Stock pursuant to a Rule 10b5-1 trading plan.

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported a transaction involving Class A Common Stock under a Rule 10b5-1 trading plan.

Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock via a Rule 10b5-1 trading plan.

Recursion Pharmaceuticals, Inc. reports a transaction by its Chief Financial Officer, Ben R. Taylor, involving Class A Common Stock.

Director Christopher Gibson has sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock for $3.10 per share, totaling $124,000, as part of a pre-arranged trading plan.

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported a transaction involving 30,000 shares of Class A Common Stock on April 7, 2026, executed under a Rule 10b5-1 trading plan.

Director Dar Zavain acquired 4,902 shares of Recursion Pharmaceuticals Class A Common Stock under the company's Outside Director Compensation Policy.

Dean Y. Li acquired 3,268 shares of Class A Common Stock in Recursion Pharmaceuticals, Inc. on April 1, 2026, as part of the company's Outside Director Compensation Policy.

Recursion Pharmaceuticals Director Christopher Gibson executed a planned sale of 40,000 Class A Common Stock shares at $3.25, following a conversion from Class B shares.

Recursion Pharmaceuticals' Chief Financial Officer, Ben R. Taylor, reported the disposition of 15,031 shares of Class A Common Stock through tax withholding and a pre-planned sale.

Recursion Pharmaceuticals director Blake Borgeson sold 170,000 shares of Class A Common Stock for $3.46 per share.

Recursion Pharmaceuticals' Chief Scientific Officer, David Hallett, reported a tax-related disposition of 11,908 Class A Common Stock shares.

A director at Recursion Pharmaceuticals, Christopher Gibson, reported the sale of 40,000 Class A Common Stock shares and tax-related withholdings under a pre-arranged plan.

Recursion Pharmaceuticals CFO Ben Taylor reported the sale of Class A Common Stock, including shares withheld for tax obligations and a sale under a 10b5-1 plan.

Recursion Pharmaceuticals CEO Najat Khan disposed of 14,280 shares of Class A Common Stock to cover tax obligations related to restricted stock units.

Recursion Pharmaceuticals CEO Najat Khan reported significant equity transactions, including RSU grants and tax-related share disposals, effective February 6, 2026.